| Followers | 0 |
| Posts | 2177 |
| Boards Moderated | 0 |
| Alias Born | 04/13/2018 |
Sunday, July 05, 2020 8:52:06 AM
Ah the oldest of all the bad faith arguments.
Well couple problems here.
1. Nader has stated multiple times the ol' reverse split is off the table. He knows that would tank us and wants to see the share holders rewarded not punished.
2. We already had multiple good news events and no reverse split. So this theory has already collapsed.
3. The authorized shares exist in case financing doesn't happen.
4. Having extra shares that you can sell provides a "poison pill defense." So a hostile takeover could be thwarted in the event another company wanted to try and get us cheap.
5. "An R/S could come before or after they begin to sell some authorized shares." Okay wow. First if you did a reverse split before selling more shares no one would buy them out of lack of confidence. Reverse splitting after selling more shares would cause a share dump and kill the company.
6. We talked about doing a reverse split before and the shareholders practically had a riot.
7. Any reverse split would have to get approval from the board of directors. The board is excited enough by the prospects that a reverse split is seen as cutting into their payday.
8. A reverse split and the chaos that would result would disrupt uplisting.
Myth Busted.
Well couple problems here.
1. Nader has stated multiple times the ol' reverse split is off the table. He knows that would tank us and wants to see the share holders rewarded not punished.
2. We already had multiple good news events and no reverse split. So this theory has already collapsed.
3. The authorized shares exist in case financing doesn't happen.
4. Having extra shares that you can sell provides a "poison pill defense." So a hostile takeover could be thwarted in the event another company wanted to try and get us cheap.
5. "An R/S could come before or after they begin to sell some authorized shares." Okay wow. First if you did a reverse split before selling more shares no one would buy them out of lack of confidence. Reverse splitting after selling more shares would cause a share dump and kill the company.
6. We talked about doing a reverse split before and the shareholders practically had a riot.
7. Any reverse split would have to get approval from the board of directors. The board is excited enough by the prospects that a reverse split is seen as cutting into their payday.
8. A reverse split and the chaos that would result would disrupt uplisting.
Myth Busted.
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
